JPRN-UMIN000003867已完成1 期
Phase 1 study of fludarabine combined with rituximab followed by Zevalin for patients with relapsed or refractory indolent B cell lymphoma - Fludarabine combined with rituximab followed by Zevalin for patients with relapsed or refractory indolent B cell lymphoma
Tohoku Hematology Form0 个研究点目标入组 12 人开始时间: 2010年7月5日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 79years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(a)History of hematopoietic stem cell transplantation (b)History of whole pelvic or whole abdomen radiation (c)Received G-CSF or erythropoietin or transfusion less than one week before registration (d)Taken an operation less than four weeks before registration (e)History of Zevalin therapy (f)History of the treatment of purin analogs (g)Have active systemic infections (h)Have a serious complication(cardiac dysfunction, hepatic failure, or renal failure) (i)Have a serious digestive organ symptom (j)Have a serious bleeding tendency (k) Positive for HBs antigen, HCV antibody, or HIV antibody. (l)Have an interstitial pneumonia or fibrosis (m)Active cancers (n)Have or history of autoimmune hemolytic anemia (o)Have aglucoma (p) Otherwise judged by investigator to be unsuitable
研究者
相似试验
进行中（未招募）
不适用
First line treatment with rituximab plus fludarabine, cyclophosphamide, mitoxantrone (R-FCM) and maintenance therapy with rituximab in patients diagnosed with chronic lymphocytic leukemia. Tratamiento de primera línea con rituximab combinado con fluradabina, ciclofosfamida y Mitoxantrone (R-FCM) y mantenimiento con rituximab de pacientes con leucemia linfática crónica (LLC) - R-FCM in CPatients diagnosed with chronic lymphocytic leukemia (CLL) according to the WHO guidelines, within 18 and 71 years and not previously treatedEUCTR2005-001569-33-ESDept. Hematology, Hospital Clinic60
进行中（未招募）
不适用
Fludarabine/Rituximab combined with escalating doses of Lenalidomide followed by Rituximab/Lenalidomide in untreated chronic lymphocytic leukemia (CLL) – a dose-finding study with concomitant evaluation of safety and efficacy - RevliRitntreated chronic lymphocytic leukaemia (B-CLL)MedDRA version: 9.1Level: LLTClassification code 10003946Term: B-Lymphocytic, CLL (Kiel Classification)EUCTR2008-001430-27-ATArbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH
进行中（未招募）
不适用
Fludarabine/Rituximab combined with escalating doses of Lenalidomide in untreated chronic lymphocytic leukemia (CLL)EUCTR2011-004912-43-ATArbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH
已完成
2 期
Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic LeukemiaB-cell Chronic Lymphocytic LeukemiaStage I Chronic Lymphocytic LeukemiaStage II Chronic Lymphocytic LeukemiaStage III Chronic Lymphocytic LeukemiaStage IV Chronic Lymphocytic LeukemiaNCT00098670National Cancer Institute (NCI)102
已完成
2 期
Phase II randomised study of fludarabine/cyclophosphamide combination with or without rituximab in patients with untreated mantle cell lymphomaMantle cell lymphomaCancerISRCTN81133184niversity College London (UK)151